Basit öğe kaydını göster

Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey

dc.contributor.authorHarmanci, Koray
dc.contributor.authorCokugras, Haluk
dc.contributor.authorKilinc, Ayse Ayzit
dc.contributor.authorAl Shadfan, Lina Muhammed
dc.contributor.authorYazan, Hakan
dc.contributor.authorAltintas, Derya Ufuk
dc.contributor.authorKaragoz, Dilek
dc.contributor.authorDemir, Esen
dc.contributor.authorOzturk, Gokcen Kartal
dc.contributor.authorBingol, Aysen
dc.contributor.authorBasaran, Abdurrahman Erdem
dc.contributor.authorSapan, Nihat
dc.contributor.authorCekic, Sukru
dc.contributor.authorCelebioglu, Ebru
dc.contributor.authorAslan, Ayse Tana
dc.contributor.authorGursoy, Tugba Ramasli
dc.contributor.authorTugcu, Gokcen
dc.contributor.authorOzdemir, Ali
dc.contributor.authorErcan, Omur
dc.contributor.authorYildirim, Gonca Kilic
dc.contributor.authorKose, Mehmet
dc.contributor.authorHangul, Melih
dc.contributor.authorSuleyman, Ayse
dc.contributor.authorYuksel, Hasan
dc.contributor.authorYilmaz, Ozge
dc.contributor.authorOzcan, Gizem
dc.contributor.authorTopal, Erdem
dc.contributor.authorCan, Demet
dc.contributor.authorEkren, Pervin Korkmaz
dc.contributor.authorCaltepe, Gonul
dc.contributor.authorKilic, Mehmet
dc.contributor.authorOzdogan, Sebnem
dc.contributor.authorDogru, Deniz
dc.contributor.authorCobanoglu, Nazan
dc.contributor.authorOzcelik, Ugur
dc.contributor.authorÇAKIR, Erkan
dc.contributor.authorEyuboglu, Tugba Sismanlar
dc.contributor.authorPekcan, Sevgi
dc.contributor.authorCinel, Guzin
dc.contributor.authorYalcin, Ebru
dc.contributor.authorKiper, Nural
dc.contributor.authorEMİRALİOĞLU, NAGEHAN
dc.contributor.authorSen, Velat
dc.contributor.authorTAMAY, Zeynep Ülker
dc.contributor.authorSen, Hadice Selimoglu
dc.date.accessioned2021-03-02T17:19:40Z
dc.date.available2021-03-02T17:19:40Z
dc.date.issued2020
dc.identifier.citationCobanoglu N., Ozcelik U., ÇAKIR E., Eyuboglu T. S. , Pekcan S., Cinel G., Yalcin E., Kiper N., EMİRALİOĞLU N., Sen V., et al., "Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey", PEDIATRIC PULMONOLOGY, cilt.55, ss.2302-2306, 2020
dc.identifier.issn8755-6863
dc.identifier.othervv_1032021
dc.identifier.otherav_c92b1d59-6c5e-44d5-991a-cd87d158caef
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3680
dc.identifier.urihttps://doi.org/10.1002/ppul.24854
dc.description.abstractBackground A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectSOLUNUM SİSTEMİ
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectÇocuk Sağlığı ve Hastalıkları
dc.subjectPEDİATRİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titlePatients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
dc.typeMakale
dc.relation.journalPEDIATRIC PULMONOLOGY
dc.contributor.departmentAnkara Üniversitesi , ,
dc.identifier.volume55
dc.identifier.issue9
dc.identifier.startpage2302
dc.identifier.endpage2306
dc.contributor.firstauthorID2215268


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster